论文部分内容阅读
作者在前一研究中强调了测定血清铜(SCu)水平用以对肝肿瘤和肝硬化的鉴别诊断。本研究旨在判断SCu对有慢性肝病体征的患者有否预后价值,与肝肿瘤患者的生存时间是否相关。本研究包括36例(男25,女11)原发性肝肿瘤患者,年龄14～75岁,其中32例为肝细胞癌(10例伴有肝硬化),其余4例为胆管癌。15例作过部分肝切除,其余患者未作过特殊治疗。所有患者的诊断均经组织学检查证实。对照组为47例(男31,女16)年龄相仿的肝硬化患者,均经CT或超声断层摄影,腹腔镜或剖腹术和活检等排除了肿瘤的存在。各例均未使用过类固醇,抗生素或可能终止胆汁郁积的其他药物,也未接受过抑菌治疗。有传染性,炎症或系统性疾病者则排除之。入院时,所有患者都作常规生化测定,包括用原子吸收法测定
In the previous study, the authors highlighted the determination of serum copper (SCu) levels for the differential diagnosis of liver tumors and cirrhosis. The purpose of this study was to determine whether SCu has a prognostic value in patients with chronic liver disease signs and whether it is related to the survival of patients with liver cancer. This study included 36 patients (25 males and 11 females) with primary liver tumors of 14-75 years of age, of whom 32 were hepatocellular carcinoma (10 with cirrhosis) and the remaining 4 were cholangiocarcinoma. Fifteen patients underwent partial hepatectomy and the remaining patients had no specific treatment. All patients were diagnosed by histological examination confirmed. The control group consisted of 47 patients (31 males and 16 females) with similar age and liver cirrhosis. The tumors were excluded by CT or ultrasonography, laparoscopy or laparotomy and biopsy. No cases of steroids, antibiotics or other drugs that may stop the cholestasis in each case, nor have they been treated with antibacterials. Infectious, inflammatory or systemic diseases are excluded. At admission, all patients were routinely biochemically determined, including by atomic absorption spectroscopy